Benton Annaleigh, Liu Bozhi, Gartenhaus Lauren E, Hanna Jason A
Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Purdue University Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.
Mol Oncol. 2025 Apr;19(4):965-983. doi: 10.1002/1878-0261.13744. Epub 2024 Oct 5.
Angiosarcoma is a cancer that develops in blood or lymphatic vessels that presents a significant clinical challenge due to its rarity and aggressive features. Clinical outcomes have not improved in decades, highlighting a need for innovative therapeutic strategies to treat the disease. Genetically, angiosarcomas exhibit high heterogeneity and complexity with many recurrent mutations. However, recent studies have identified some common features within anatomic and molecular subgroups. To identify potential therapeutic vulnerabilities, it is essential to understand and integrate the mutational landscape of angiosarcoma with the models that exist to study the disease. In this review, we will summarize the insights gained from reported genomic alterations in molecular and anatomic subtypes of angiosarcoma, discuss several potential actionable targets, and highlight the preclinical disease models available in the field.
血管肉瘤是一种发生于血管或淋巴管的癌症，因其罕见性和侵袭性特征而带来重大临床挑战。几十年来临床治疗效果并未改善，这凸显了需要创新治疗策略来治疗该疾病。在基因层面，血管肉瘤表现出高度异质性和复杂性，存在许多复发性突变。然而，最近的研究已经在解剖学和分子亚组中发现了一些共同特征。为了确定潜在的治疗弱点，了解血管肉瘤的突变情况并将其与现有的疾病研究模型相结合至关重要。在本综述中，我们将总结血管肉瘤分子和解剖学亚型中已报道的基因组改变所获得的见解，讨论几个潜在的可操作靶点，并强调该领域可用的临床前疾病模型。
